Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin
- 1 April 1989
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 63 (12), 826-832
- https://doi.org/10.1016/0002-9149(89)90051-9
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Ketanserin in Parenteral Treatment of Acute Essential HypertensionJournal of Cardiovascular Pharmacology, 1987
- Central Hypotensive Activity of Ketanserin in CatsJournal of Cardiovascular Pharmacology, 1987
- Role of α-Adrenergic Blockade in the Cardiovascular Actions of KetanserinJournal of Cardiovascular Pharmacology, 1987
- Pathophysiological Relevance of SerotoninJournal of Cardiovascular Pharmacology, 1987
- Cardiovascular Effects of SerotoninJournal of Cardiovascular Pharmacology, 1987
- Serotonergic Mechanisms in Isolated Human Peripheral Arteries and VeinsJournal of Cardiovascular Pharmacology, 1985
- Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension.Heart, 1984
- Pharmacokinetics and Pharmacodynamics of the 5-HT2 Receptor Antagonist Ketanserin in ManJournal of Cardiovascular Pharmacology, 1983
- The effect of a 5‐HT antagonist, ketanserin, on blood pressure, the renin‐angiotensin system and sympathoadrenal function in normal man.British Journal of Clinical Pharmacology, 1983
- Ketanserin, a novel 5‐hydroxytryptamine antagonist: monotherapy in essential hypertension.British Journal of Clinical Pharmacology, 1983